MedPath

Pyrotech Therapeutics, Inc.

Pyrotech Therapeutics, Inc. logo
🇨🇳China
Ownership
Holding
Established
2020-10-22
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
Drug: Combination of PTT-936 and anti-PD-1/L1 therapy
First Posted Date
2024-02-06
Last Posted Date
2025-03-12
Lead Sponsor
Pyrotech Therapeutics, Inc.
Target Recruit Count
68
Registration Number
NCT06244992
Locations
🇺🇸

Precision NextGen Oncology and Research Center, Beverly Hills, California, United States

🇺🇸

D&H Cancer Research Center, Margate, Florida, United States

🇺🇸

The START Center, San Antonio, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.